IPCAs 4QFY18 revenue grew ~18% YoY to INR7.8b (est. of INR7.7b), primarily led by robust ~15% YoY growth in the formulation segment. of INR1.6b), with the margins at 14% v/s 18.8% in 3QFY18 and 10% in 4QFY17. Sequential contraction in the EBITDA margin can be attributed to high other expenses (+600bp QoQ). PAT came in 30 May 2018 at INR513m (est. For FY18, sales, EBITDA and PAT stood at INR32.8b (+2.3%), INR4.